Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

BackgroundThe combination of BRAF and MEK inhibitors represents the standard of care treatment for patients with metastatic BRAF-mutated melanoma, notwithstanding the high frequency of emergent resistance. Moreover, therapeutic options outside clinical trials are scarce when patients have progressed...

Full description

Bibliographic Details
Main Authors: Anna Stagno, Sabrina Vari, Alessio Annovazzi, Vincenzo Anelli, Michelangelo Russillo, Francesco Cognetti, Virginia Ferraresi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
metastatic melanoma
BRAF V600 mutation
drug resistance
targeted therapy
BRAF inhibitor
MEK inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.645008/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.645008/full

Similar Items